Filing Flows › Comparisons › DARE vs BTAIQ
Dare Bioscience vs BioXcel Therapeutics: DARE and BTAIQ compared
Dare Bioscience is the larger company: $188K of revenue in its latest quarter (Q2 2026) against $182K for BioXcel Therapeutics (Q2 2026).
Where the money goes: DARE and BTAIQ
Dare Bioscience (DARE) · Q2 2026
Dare Bioscience, Q2 2026: revenue $188K, net loss $3.0M, operating cash flow −$6.8M. The chart follows the revenue to costs, profit and cash.
BioXcel Therapeutics (BTAIQ) · Q2 2026
BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year), net loss $14.7M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
| Dare Bioscience (DARE) | BioXcel Therapeutics (BTAIQ) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $188K | $182K |
| Revenue growth, Y/Y | — | +52% |
| Operating margin | n/m | n/m |
| Net earnings | −$3.0M | −$14.7M |
| Operating cash flow | −$6.8M | −$6.1M |
Questions
Which is bigger, Dare Bioscience or BioXcel Therapeutics?
Dare Bioscience is the larger company: $188K of revenue in its latest quarter (Q2 2026) against $182K for BioXcel Therapeutics (Q2 2026).
More: Dare Bioscience earnings · how Dare Bioscience makes money · BioXcel Therapeutics earnings · how BioXcel Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.